recent pharma news

Oct 31, 2019

AstraZeneca has announced the licensing-out of two of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. According to the deal signed between the companies, AZ will receive an upfront payment of USD 178 Million, in addition to other payments upon achieving sales milestones...

Oct 24, 2019

Rapt Therapeutics files for IPO at $75M Rapt Therapeutics, based in the US, filed to raise to $75 million in its IPO. This had come after five months when the company had retitled itself, which was earlier known as Flx Bio and after three months, it had filed its initial S-1 form with the hope to gain $86 millio...

Oct 22, 2019

The US FDA today has given its nod to Trikafta (elexacaftor/ivacaftor/tezacaftor) of Vertex Pharmaceuticals, the first of its kind triple combination therapy for the patients with cystic fibrosis. The drug, Trikafta, has been approved for patients of age 12 years and older who have at least one F508del mutation...

Oct 15, 2019

ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the im...

Oct 08, 2019

AngioDynamics, an innovative medical devices provider, has signed an upfront USD 46 Million deal to acquire Eximo Medical. AngioDynamics is a leading player in manufacturing medical devices for vascular access, peripheral vascular disease, and oncology. The acquisition of Eximo Medical will increase the portfol...

Oct 03, 2019

Roche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug, Tecentriq, combined with Pt-based chemotherapy showed a noteworthy improvement in patients with untreated advanced bla...

Oct 01, 2019

Stipe Therapeutics (STipe) has raised USD 22 Million to move forward its clinical development of novel candidates to target intracellular protein-protein interactions of the STING Pathway. The financing round was led by Sunstone Life Science Ventures Fund IV, Novo Holdings, Arix Bioscience, and Wellington Partne...

Sep 26, 2019

European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma. Nirogacestat is a selective oral small molecule, gamma-secretase inhibitor under development by SpringWork Therapeutics. Currently, in Phase III development, the drug is investigated for the treatment o...

Sep 24, 2019

Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic drugs to target diseases. Study of changes in gene expressions without any changes in the DNA sequence is known as Epigenetics.  This oft...

Sep 19, 2019

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...